Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

Despite these positive results, the company faced a setback as its Phase 3 RELATIVITY-098 trial for Opdualag in melanoma did not meet its primary endpoint. In addition, Bristol Myers Squibb shared ...

Bristol-Myers Squibb has won FDA approval for the ... combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with unresectable ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...